VIGAFYDE™ (vigabatrin)
Monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
To read important safety information, including the boxed warning, please click here.

